- Sep 2024
The baseline panel already showed early metabolic drift — an above-range HbA1c and borderline atherogenic lipids — against an otherwise well profile.
HbA1cHigh at baseline→ Emerging dysglycaemiaHbA1c sat just above range at the first panel, marking the earliest sign of glycaemic drift.
LDL CholesterolHigh at baseline→ Atherogenic lipid patternLDL was already above target at baseline, establishing an atherogenic starting point.
TriglyceridesHigh at baseline→ Atherogenic lipid patternTriglycerides opened above range, consistent with early insulin-driven lipid handling.
hs-CRPHigh at baseline→ Low-grade inflammationA mildly raised hs-CRP established a low-grade inflammatory backdrop from the outset.
Vitamin D, 25-OHLow at baseline→ Micronutrient statusVitamin D was marginally low at baseline, the first of several modest micronutrient signals.
- Jun 2025
By the interval panel the drift was consolidating: glycaemia and the hepatic enzymes stepped up, and fasting insulin crossed above range.
Fasting GlucoseCrossed above rangePrev: 98→ Emerging dysglycaemiaFasting glucose moved from the high-normal baseline to frankly above range at this panel.
Fasting InsulinCrossed above rangePrev: 11→ Emerging dysglycaemiaFasting insulin crossed above range, confirming the glycaemic change was insulin-driven.
Alanine Aminotransferase (ALT)Crossed above rangePrev: 48→ Hepatic steatosis signatureALT crossed above range and above AST — the transaminase pattern typical of fatty liver.
hs-CRPStill elevatedPrev: 1.8→ Low-grade inflammationhs-CRP continued to rise, tracking the widening metabolic load rather than any infection.
- Mar 2026
The latest panel confirmed the trajectory: insulin resistance is now established, HDL has fallen below range, while the blood count and renal function stayed stable.
HbA1cTrending upPrev: 5.9→ Emerging dysglycaemiaHbA1c reached 6.1%, completing a consistent upward slope across all three panels.
HOMA-IRPeak valuePrev: 3.6→ Emerging dysglycaemiaThe derived HOMA-IR reached 5.0, its highest value and well above the insulin-sensitive range.
HDL CholesterolCrossed below rangePrev: 43→ Atherogenic lipid patternHDL fell below the protective threshold, widening the atherogenic lipid picture.
HaemoglobinStable in range→ Blood count preservedHaemoglobin held steady and in range, with no anaemia to complicate the metabolic picture.
eGFRStable→ Renal function preservedEstimated GFR was unchanged and only mildly reduced for age, so renal function is preserved.
Insulin resistance has consolidated across three panels
The clearest longitudinal signal is a steady progression into insulin resistance. HbA1c rose monotonically from 5.7% to 6.1%, fasting glucose from a high-normal 98 to 112 mg/dL, and fasting insulin from 11 to 18 µIU/mL, driving the derived HOMA-IR from 2.7 to 5.0. Read as a single trend rather than three separate flags, this is a reversible pre-diabetic trajectory that is still short of diabetes — which is precisely why the window to intervene is now. A confirmatory OGTT with paired insulin would stage it and set a clean pre-intervention baseline.
The atherogenic lipid pattern is widening
The lipids have moved with the metabolic thread rather than independently. LDL climbed from 142 to 165 mg/dL, triglycerides from 168 to 210 mg/dL, and HDL fell from a protective 43 to a sub-range 38 mg/dL — the classic pattern of insulin-driven lipid handling. Two markers extend the risk beyond the standard panel: lipoprotein(a) at 78 nmol/L, a largely genetic and LDL-independent factor, and a homocysteine of 14.2 µmol/L. Because calculated LDL can under-read particle burden when triglycerides are high, an ApoB would refine both the risk and the treatment intensity.
A fatty-liver enzyme signature has emerged
A hepatic steatosis signature developed over the window. ALT crossed above range in mid-2025 and reached 62 U/L, exceeding AST (48 U/L), with GGT elevated at 74 U/L — a fat-pattern rather than a cholestatic or synthetic-failure picture, since alkaline phosphatase, bilirubin and albumin all stayed normal. Normal enzymes would not exclude fibrosis, and bloods alone cannot stage it, so imaging and a non-invasive fibrosis estimate are the logical next step.
Low-grade inflammation is tracking the metabolic load
Inflammation has risen in step with the metabolic drift rather than pointing to infection. hs-CRP roughly doubled from 1.8 to 3.4 mg/L across the panels, with a mildly raised ESR and a persistently normal white-cell count. This is the signature of adipose-driven, cardiometabolic inflammation, and it predicts that the marker should fall as metabolic control improves — giving a convenient way to track response.
The three-panel trajectory establishes insulin resistance but cannot distinguish it from early beta-cell limitation — a distinction that shapes both prognosis and therapy. An oral glucose tolerance test with paired insulin, or a C-peptide, would settle that question and set a clean pre-intervention baseline. This is advised rather than urgent, because no value has reached a diabetic threshold; a repeat HbA1c at three months would run alongside it.
With a climbing LDL, an elevated lipoprotein(a), a raised homocysteine and a borderline office blood pressure, an LDL-only view under-represents the risk. A formal 10-year risk estimate, an ApoB to quantify atherogenic particle burden, and an ambulatory blood-pressure record would let the true vascular burden be staged and a statin discussion be grounded in data rather than a single panel.
The emerging ALT-over-AST pattern with a raised GGT justifies a liver ultrasound and a non-invasive fibrosis estimate such as FIB-4 or transient elastography. Normal albumin and bilirubin are reassuring for synthetic function but neither confirms nor stages steatosis, and the stage changes both surveillance and how aggressively to pursue metabolic reversal.
Because every headline marker is defined by its trend rather than a single value, a repeat metabolic and lipid panel at three months is the natural way to confirm the drift is reversing under intervention. A single follow-up panel showing the slope flattening would be the strongest evidence that the plan is working.
Vitamin D has been low across the panels and magnesium sits just below range — each modest alone but relevant to insulin sensitivity and vascular tone, and both low-risk to correct. Repletion, with a recheck of B12 and folate in the context of the raised homocysteine, reinforces the primary metabolic and vascular goals rather than competing with them.
The clinical backdrop is deliberately clean: a 58-year-old male with three fasting panels on record over eighteen months and no documented diagnoses, medications, supplements, or procedures. That absence is what makes the trajectory interpretable — the movement in HbA1c, glucose, insulin, lipids and the liver enzymes cannot be attributed to a new drug or an intercurrent illness, so it most plausibly reflects an underlying metabolic process. The gaps that remain are diagnostic rather than historical: there is no OGTT, no ApoB or particle count, no liver imaging, and only a single office blood pressure, each of which is addressed in the follow-up plan. A reconciled anthropometric record — weight, BMI and waist circumference — would further anchor the cardiometabolic reading.
